Mizuho analyst Uy Ear raised the firm’s price target on Alkermes to $37 from $36 and keeps a Buy rating on the shares. The analyst expects "solid" Q1 results and says Alkermes remains a top pick. The firm continues to see potential upside from a Vivitrol patent settlement, Lybalvi, low pipeline expectations, and value creation from the planned oncology spin-off.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALKS: